This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20251210926005\/en\/<\/a><\/p>\n OrangeTwist<\/p>\n<\/div>\n \nSupporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and most sophisticated platforms across a wide range of medical disciplines, continuously integrating this knowledge into a coherent platform strategy. With more than 25 years of history, the Company has developed a scalable operating model, deep clinical expertise, and a strong track record of disciplined growth\u2014foundations that position SBC Medical to execute successfully on its next phase of international expansion.<\/p>\n \nThis investment marks the beginning of SBC Medical\u2019s full-scale strategic expansion in the U.S. market through a committed partnership with OrangeTwist, and both companies will pursue joint operations that leverage cross-border synergies between the U.S. and Asia to support long-term growth opportunities.<\/p>\n \nFounded in 2015, OrangeTwist specializes in non-invasive aesthetic treatments and currently operates 24 locations across six U.S. states. With strong medical oversight and data-driven clinical operations, the company offers a comprehensive portfolio of injectable, energy-based, and regenerative treatments. Its advanced management system integrating procurement, clinical workflows, and real-time KPI tracking provides operational consistency and supports scalable growth.<\/p>\n Comment from Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Comment from Clint Carnell, Co-founder of OrangeTwist SBC Medical Global Growth Strategy \nThis partnership signifies the start of SBC Medical\u2019s Phase 1 market entry initiative and lays the groundwork for future phases of scale and market leadership. By integrating a sustainable model focused on personal well-being and high-quality medical outcomes, SBC Medical aims to deliver differentiated value to customers in the U.S. and Asia, while building diversified and resilient revenue streams across geographies.<\/p>\n \n\u25cf Global Expansion Strategy Designed for Sustainable Earnings Growth 1. Partnering with high-performing regional operators<\/b> with demonstrated execution capability, strong brand presence, and scalable business models; \nThe Company is focused on high-growth categories within health and wellness\u2014including regenerative medicine, aesthetic medicine, and wellness solutions\u2014while also exploring next-generation opportunities in human optimization, longevity science, and Medicine 4.0. SBC Medical continues to evaluate strategic medical technology platforms such as AI-enabled diagnostics, telemedicine capabilities, and patient-experience technologies that align with its long-term growth priorities.<\/p>\n \u25cf Three-Phase Global Expansion Roadmap Phase 1: Entry (2025\u20132026) Phase 2: Scale (2027\u20132028) Phase 3: Leadership (2029 onward) \nSBC Medical believes this disciplined, phased approach\u2014combined with the stability and profitability of its Japan business\u2014positions the Company to deliver sustainable long-term growth, improved earnings quality, and increasing global brand value.<\/p>\n About SBC Medical Group Holdings Incorporated About OrangeTwist About Hildred About Athyrium Forward-Looking Statements View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251210926005\/en\/<\/a><\/span><\/p>\n SBC Medical Group Holdings Incorporated ICR LLC (US Time) KEYWORDS:<\/b> Washington California New Jersey Texas United States Japan North America Asia Pacific<\/p>\n INDUSTRY KEYWORDS:<\/b> Other Retail Surgery Health Hospitals Fitness & Nutrition Luxury Retail Other Health<\/p>\n![\"OrangeTwist\"](\"https:\/\/mms.businesswire.com\/media\/20251210926005\/en\/2679431\/4\/SKY1.jpg\")
<\/p>\n
\n
<\/b>\u201cOrangeTwist has solidified its leadership in the U.S. market by consistently delivering exceptional quality and outstanding client experiences in non-invasive aesthetic medicine. We look forward to combining their strengths with our expertise and global network to accelerate growth across Asia and beyond.\u201d<\/p>\n
\n
<\/b>\u201cSBC Medical has built one of the most respected and sophisticated aesthetic brands internationally. Their entry into the U.S. through a partnership with OrangeTwist provides a uniquely strong operational foundation and accelerates their ability to scale in one of the largest and fastest-growing aesthetic markets in the world.\u201d<\/p>\n
\n
<\/b>SBC Medical\u2019s investment in OrangeTwist is the first step in a structured, multi-year roadmap to establish a leading position in the U.S. medical aesthetics and wellness market. The partnership enables both companies to leverage cross-border synergies across clinical protocols, technology adoption, operational efficiency, and commercial strategy.<\/p>\n
\n
<\/b>SBC Medical views international expansion\u2014particularly in the United States and Southeast Asia\u2014as a central pillar of its long-term value creation strategy. The Company\u2019s global expansion thesis is guided by three core principles<\/p>\n
\n
2. Deploying SBC Medical\u2019s differentiated operating expertise<\/b>, including leadership in advanced aesthetic treatments, operational excellence, and clinical safety, to drive performance uplift across partner networks; and
\n
3. Securing first-mover advantages<\/b> through access to emerging medical technologies, proprietary treatment platforms, and information-sharing mechanisms that support future innovation and margin expansion.<\/p>\n
\n
<\/b>The OrangeTwist partnership forms part of SBC Medical\u2019s structured global expansion roadmap:<\/p>\n
\n
<\/b>Deepen market understanding, build strategic partnerships, and deploy minority investments that create optionality for future expansion.<\/p>\n
\n
<\/b>Leverage accumulated market intelligence and SBC Medical\u2019s proven operating model to pursue selective acquisitions and joint ventures capable of accelerating growth and strengthening competitive positioning.<\/p>\n
\n
<\/b>Establish SBC Medical as a leading operator in the United States and other priority international markets, supported by diversified revenue streams, scalable clinical platforms, and technology-driven operating leverage.<\/p>\n
\n
<\/b>SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations as well as medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000\u00ae Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose \u201cContributing to the well-being of people around the world through medical innovation,\u201d SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
\n
For more information, visit https:\/\/sbc-holdings.com\/
\n<\/a>
For more insights and updates from SBC Holdings, follow us on LinkedIn<\/a>\u3000<\/p>\n
\n
<\/b>OrangeTwist is a fast-growing national provider of medically supervised aesthetic and wellness treatments with 24 locations in CA, TX, WA, NV, CO, and NJ. OrangeTwist was co-founded by world-renowned medical director Dr. Grant Stevens, M.D. F.A.C.S. and Clint Carnell, an experienced healthcare services\/medical technology executive and former CEO of the HydraFacial Company. The company delivers a curated portfolio of injectable, energy-based, and regenerative treatments through a hospitality-driven experience supported by best-in-class clinicians and strong medical oversight.
\n
For more information, visit www.orangetwist.com<\/a>.<\/p>\n
\n
<\/b>Hildred is a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies. The firm specializes in partnering with management teams to help them scale their platforms, generate earnings growth, promote strategic and operational improvements, generate business development, and drive multiple expansion. For more information, visit www.hildred.com<\/a> and follow the firm on LinkedIn<\/a>.<\/p>\n
\n
<\/b>Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $4.6 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. For more information, please visit www.athyrium.com<\/a>.<\/p>\n
\n
<\/b>This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company\u2019s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company\u2019s control. These forward-looking statements reflect the Company\u2019s current views with respect to, among other things, the Company\u2019s strategic investment and alliance with OrangeTwist, product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201ccontemplates,\u201d \u201cestimates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cprojected,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ctargets\u201d or \u201chopes\u201d or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management\u2019s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading \u201cRisk Factors\u201d and elsewhere in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), which are accessible on the SEC\u2019s website at www.sec.gov<\/a>.<\/p>\n<\/p>\n
\n
<\/b>Hikaru Fukui \/ Head of IR Department; E-mail: ir@sbc-holdings.com
\n<\/a>
Akiko Wakiyama \/ Head of Public Relations; E-mail: pr@sbc.or.jp<\/a><\/p>\n
\n
<\/b>Bill Zima \/ Managing Partner; E-mail: bill.zima@icrinc.com<\/a><\/p>\n
![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20251210926005\/en\/2679431\/3\/SKY1.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251210926005\/en\/2666670\/3\/SBC_logo_H_Gray_6.jpg\"){kind=logo}
<\/td>\n<\/tr>\n